 |
PDBsum entry 3log
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Inhibition studies of mycobacterium tuberculosis salicylate synthase (mbti).
|
 |
|
Authors
|
 |
A.Manos-Turvey,
E.M.Bulloch,
P.J.Rutledge,
E.N.Baker,
J.S.Lott,
R.J.Payne.
|
 |
|
Ref.
|
 |
Chemmedchem, 2010,
5,
1067-1079.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Mycobacterium tuberculosis salicylate synthase (MbtI), a member of the
chorismate-utilizing enzyme family, catalyses the first committed step in the
biosynthesis of the siderophore mycobactin T. This complex secondary metabolite
is essential for both virulence and survival of M. tuberculosis, the etiological
agent of tuberculosis (TB). It is therefore anticipated that inhibitors of this
enzyme may serve as TB therapies with a novel mode of action. Herein we describe
the first inhibition study of M. tuberculosis MbtI using a library of
functionalized benzoate-based inhibitors designed to mimic the substrate
(chorismate) and intermediate (isochorismate) of the MbtI-catalyzed reaction.
The most potent inhibitors prepared were those designed to mimic the enzyme
intermediate, isochorismate. These compounds, based on a 2,3-dihydroxybenzoate
scaffold, proved to be low-micromolar inhibitors of MbtI. The most potent
inhibitors in this series possessed hydrophobic enol ether side chains at C3 in
place of the enol-pyruvyl side chain found in chorismate and isochorismate.
|
 |
|
|
|
|
 |